Change in pruritus in patients with primary biliary cholangitis and moderate to severe pruritus: a pooled analysis from the RESPONSE and ENHANCE studies

Introduction: Seladelpar (SEL) is a first-in-class delpar (selective PPAR-delta agonist) indicated for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as a monotherapy in pts unable to tolerate UDCA. In two Phase 3, placebo (PBO)-controlled trials (ENHANCE [NCT03602560] and RESPONSE [NCT04620733]), SEL significantly reduced pruritus among pts who had moderate to severe pruritus (numerical rating scale [NRS]≥4) at baseline (BL).